tw0122
9月前
BioStrand, ImmunoPrecise Antibodies’ Subsidiary, Announces Immediate Commercial Offering of Groundbreaking Software with Customizable Interface for AI-Driven Drug Discovery
Source: Business Wire
-BioStrand now offers a Customizable Application Programming Interface (API) with its new software offering, LENSai API, featuring the ability to integrate sizable databases and electronic health records with large language models.
-BioStrand’s novel software is rapidly and directly integrable into pharmaceutical, healthcare, and technology companies to enhance drug discovery capabilities.
-This proprietary software provides the integration of electronic health records, enhancing AI-driven drug discovery and development for industry professionals.
ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“ImmunoPrecise” or “IPA” or the “Company”), a leader in AI-driven biotherapeutic research and technology, today announces the commercial release of LENSai API, hereafter referred to as the ‘software’, by its subsidiary, BioStrand. This advanced AI-driven software solution is available immediately.
More details on this new offering will be unveiled today at 2:00 pm ET, with an additional presentation, live demonstration, and interview at 6:30 pm ET, all taking place at the InterSystems Global Summit 2024. This premier event, which attracts over 1,200 industry leaders from more than 28 countries, showcases the latest innovations in the field.
IPA, the #1 ranked contract research organization by Roots Analysis2, serves 19 of the top 20 global pharmaceutical companies and over 600 clients in the pharmaceutical and biotech industries. Leveraging feedback from these long-term relationships, the development of this AI-driven software is in direct response to meeting ongoing industry pain points and needs. These new software capabilities demonstrate innovation by combining BioStrand’s patented LENSai technology with electronic health records through a customizable interface to enable unprecedented research and drug discovery capabilities.
Dr. Dirk Van Hyfte is leading the launch of this exciting integration, enabling industry professionals to quickly and easily access and merge patient data, company research data, and extensive life science databases. Through this new release, corporations will be able to analyze major datasets related to generating novel and potentially safer and more effective drugs, as the BioStrand team continues to develop a full LENSai data management platform, expected to be released in Q1/Q2 2025.
Dr. Dirk Van Hyfte stated, "We have received significant interest in our new technology from large healthcare, pharmaceutical, and technology companies. They are keen on accessing our unique capabilities through an integration that enables them to benefit directly from BioStrand's novel applications for data analysis and cutting-edge drug discovery. The Company regards the commercial launch of this pioneering software as its most significant AI breakthrough to date, poised to significantly enhance global drug discovery and development processes. By integrating BioStrand’s software with electronic health records, and adding BioStrand’s application programming interface, we have surpassed internal timelines and milestones, supporting the rapid commercialization of these high-demand capabilities."
These new commercial capabilities will significantly enhance BioStrand’s ability to commercialize:
Partnerships with Large Companies: Major pharmaceutical, technology, and healthcare companies will be able to rapidly leverage BioStrand’s new software capabilities through partnerships that may include upfront payments, clinical milestones and commercial royalties.
Subscription Model: BioStrand is offering a subscription service that enables a wide range of technology, healthcare, and pharmaceutical companies to access BioStrand’s unique capabilities using integration of the software into their existing platforms, with a strong probability of enhancing their drug discovery and development programs.
In light of the upcoming presentation at the InterSystem’s Global Summit 2024, Dr. Dirk Van Hyfte has requested that the live podcast, media events, and interviews be recorded and made available to the public whenever possible. We also encourage everyone who can attend the live demonstration at the summit to join and support this exciting public commercial launch. You can register: InterSystems Global Summit 2024 Registration.
1www.strategyand.pwc.com/de/en/industries/pharma-life-science/re-inventing-pharma-with-artificial-intelligence.html
2ROOTS 2022, Antibody Discovery Services and Platforms Market (4th Edition), 2021-2035; pp.118
About ImmunoPrecise Antibodies Ltd.
The IPA Family is a biotherapeutic research and technology group that leverages systems biology, multi-omics modelling and complex artificial intelligence systems to support its proprietary technologies in bioplatform-based antibody discovery. Services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners in their quest to discover and develop novel biologics against the most challenging targets. ImmunoPrecise Antibodies Ltd. has several subsidiaries in North America and Europe including entities such as Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd. and ImmunoPrecise Antibodies (Europe) B.V. (collectively, the “IPA Family”).
AveragePenny
2年前
$IPA - "Today, don't miss the Market @RadiusResearch live interview with Dr. Jennifer Bath, IPA CEO. Gain insight into the future of AI in drug discovery, with a post interview Q&A session. Today 4PM EST."
Today, don't miss the Market @RadiusResearch live interview with Dr. Jennifer Bath, IPA CEO. Gain insight into the future of AI in drug discovery, with a post interview Q&A session. Today 4PM EST.
Register now: https://t.co/RxnTkEvDmQ $IPA pic.twitter.com/KOU9KnIrj3— IPA (ImmunoPrecise Antibodies) (@ImmunoPrecise) July 19, 2023
AveragePenny
3年前
IMMUNOPRECISE ANTIBODIES LTD (NASDAQ: $IPA ): CRYSTAL RESEARCH ASSOCIATES ISSUES RESEARCH REPORT
https://frontdesknews.com/2022/05/20/immunoprecise-antibodies-ltd-nasdaqipa-crystal-research-associates-issues-research-report/
Immunoprecise Antibodies Ltd (NASDAQ:IPA) is a full-service contract research organization (CRO) for therapeutic antibody discovery and development. The Company’s technology suite supports the biopharmaceutical industries in their pursuit to discover and develop novel, therapeutic antibodies against various disease targets.
Crystal Research Associates issued an research report on the company. The report states IPA is positioned as a leader in human therapeutic antibody discovery and development, disrupting the conventional multivendor drug discovery model by modernizing the antibody lead candidate selection and downstream development processes.
The Company is addressing one of the greatest challenges in generating new therapies, the lack of access to rigorous and innovative technologies (to serve a $30 billion market and growing).
IPA’s strategy is backed by expanding trends as pharmaceutical/biotechnology companies look to outsource research, improve efficiency, lower development costs, increase turnaround time, and gain access to integrated expertise.
AveragePenny
3年前
$IPA Selected to Work with Elektrofi on COVID-19 Therapeutic Delivery and Future Pandemic Preparation under SBIR Contract from Defense Health Agency within US Department of Defense
https://www.businesswire.com/news/home/20220314005424/en/IPA-Selected-to-Work-with-Elektrofi-on-COVID-19-Therapeutic-Delivery-and-Future-Pandemic-Preparation-under-SBIR-Contract-from-Defense-Health-Agency-within-US-Department-of-Defense
BOSTON--(BUSINESS WIRE)--Elektrofi (ELEKTROFI, INC) & IPA (IMMUNOPRECISE ANTIBODIES LTD.) (NASDAQ: IPA) (TSXV: IPA) today announced they are entering into a collaboration to explore a high-concentration formulation of IPA’s COVID-19 antibody cocktail, PolyTope® TATX-03. This collaboration aims to generate an IND-enabling data package for the FDA for an alternatively formulated version of TATX-03, named TATX-03E, that could be easily self-administered in a non-healthcare setting. By joining forces, the parties anticipate formulating TATX-03E for stable and rapid distribution to the consumer, a drug product ideally suited to serve unmet needs for rapid deployment, field use, and higher frequency dosing for immunocompromised individuals requiring on-going access to therapies and prophylaxis.
The collaboration between Elektrofi and IPA will be supported by Elektrofi’s contract with the DHA Small Business Innovation Research (SBIR) Program within the Department of Defense (DoD). The companies will begin by conducting formulation feasibility studies followed by IND-enabling, non-clinical studies to establish safety and efficacy with the novel formulation.
“We are impressed by the neutralizing activity demonstrated by ImmunoPrecise’s antibody cocktail against current variants of concern, including Omicron. Nearly all other programs we have looked into partnering with do not demonstrate the ability to neutralize so many variants,” said Daniel Dadon, Director of Scientific Strategy at Elektrofi. “We look forward to working with IPA to develop a product that could potentially improve access to this class of life saving medicines and reduce the burden on healthcare systems.”
“Antibodies have been an essential asset for COVID-19 patients since their introduction earlier in the pandemic,” said Dr. Jennifer Bath, CEO and President of IPA. “We are excited to be working with Elektrofi and applying their formulation technology to these critical therapies, as self-administration could significantly alleviate the burden associated with COVID-19 and future pandemics, as well as other diseases.”
AveragePenny
3年前
$IPA Updates on Investigational New Drug (IND) Enabling Program for PolyTope® TATX-03
https://finance.yahoo.com/news/ipa-updates-investigational-drug-ind-130100888.html
VICTORIA, British Columbia, March 09, 2022--(BUSINESS WIRE)--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company") (NASDAQ: IPA) (TSXV: IPA) is pleased to report on the latest progress in the development of their PolyTope® TATX-03 antibody cocktail therapy with a proven strong efficacy against all tested SARS-CoV-2 variants-of-concern. The Company reports positive data indicating their recent IND-enabling animal studies do not show any observable acute adverse events, data which supports a highly positive safety profile for TATX-03 as a clinical product. In addition, results from the FDA reviewed and recommended animal study protocols demonstrate that the in vivo pharmacokinetic profiles of the individual antibodies show no aberrations, and each antibody demonstrates a characteristic human IgG1 pharmacokinetic profile.
As a prelude to a formal toxicology study, a maximum tolerated dose and a pharmacokinetic study were completed using injections of up to 12.5 times the anticipated highest dose proposed for the phase 1 clinical trial. The results did not demonstrate any adverse clinical signs, nor any observable effect in behavior, change in appetite, or change in weight, in any of the animals. In addition, monitored vitality indicators, such as body temperature, stayed within their respective physiological ranges, and no post-mortem macroscopic tissue anomalies were observed. In vivo animal serum profiles of each antibody were in full accordance with those expected for human immunoglobulins.
To promote IND approval and a seamless transition to the clinic, the company engages in on-going communications with the FDA regarding the TATX-03 data package. The FDA has advised to enhance the preclinical safety evaluation by examining the build-up of antibody serum concentrations in the laboratory animal model versus humans, recommending a study design adaptation to increase the number of injections and to monitor the elimination of antibodies from the animals. The ongoing final GLP toxicology study is therefore extended by eight weeks with the final data being available mid-June, 2022. These current advancements allow scheduling of Investigational New Drug (IND) filing to the FDA early Q3. Importantly, the timelines for completion of clinical batch production nor the launch of the intended phase 1 clinical trial are not impacted and on schedule as planned.
"The lack of any adverse event, of morbidity, of mortality, of any observable effect in any of the rodents injected with an order more of the highest intended clinical dose of TATX-03, is very encouraging and supports that we have developed a very efficacious and resilient SARS-CoV-2 therapy with an expectedly high safety profile," stated Dr. Ilse Roodink, CSO of IPA.
"Although we are awaiting the outcome of the final GLP toxicology study, all signs indicate that we have designed a safe and effective pharmaceutical," added Dr. Roodink. "We are eager to proceed quickly but carefully to the first clinical trial phase as soon as the TATX-03 drug product is ready for distribution."
Hot Features
プレミアム
ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。
glenn1919
2週前
TheFinalCD
2週前
Strukture
2月前
Monksdream
4月前
TrendTrade2016
4月前
